androstanolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids, androgens | 3927 | 521-18-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A14AA01 | ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE ANABOLIC STEROIDS Androstan derivatives |
| ATC | G03BB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 5-androstanon (3) derivatives |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:50113 | androgene |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia of chronic renal failure | indication | 49708008 | |
| Catabolic Process | indication | ||
| Turner syndrome | off-label use | 38804009 | DOID:3491 |
| Congenital hypoplastic anemia | off-label use | 88854002 | DOID:1339 |
| Hb SS disease | off-label use | 127040003 | DOID:10923 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Obstruction of bile duct | contraindication | 30144000 | |
| Renal failure syndrome | contraindication | 42399005 | DOID:1074 |
| Body fluid retention | contraindication | 43498006 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Nephrotic syndrome | contraindication | 52254009 | DOID:1184 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Peliosis hepatis | contraindication | 58008004 | DOID:914 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Cholestatic hepatitis | contraindication | 95556007 | |
| Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Hypoalphalipoproteinemia | contraindication | 190785000 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | IC50 | 6.27 | CHEMBL | |||||
| Mineralocorticoid receptor | Nuclear hormone receptor | IC50 | 6.44 | CHEMBL | |||||
| Androgen receptor | Nuclear hormone receptor | Ki | 9.70 | CHEMBL | |||||
| Aromatase | Enzyme | Ki | 6.66 | CHEMBL | |||||
| Corticosteroid-binding globulin | Secreted | Ki | 5.92 | CHEMBL | |||||
| Sex hormone-binding globulin | Secreted | Kd | 9.74 | CHEMBL | |||||
| Progesterone receptor | Nuclear hormone receptor | IC50 | 5.14 | CHEMBL | |||||
| Androgen receptor | Transcription factor | Ki | 9.57 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | Ki | 6.79 | DRUG MATRIX | |||||
| Glucocorticoid receptor | Transcription factor | IC50 | 4.70 | CHEMBL | |||||
| Androgen receptor | Transcription factor | IC50 | 9 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | IC50 | 6.36 | CHEMBL | |||||
| Mineralocorticoid receptor | Transcription factor | IC50 | 5.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07456 | KEGG_DRUG |
| C0038148 | UMLSCUI |
| CHEBI:16330 | CHEBI |
| DHT | PDB_CHEM_ID |
| CHEMBL27769 | ChEMBL_ID |
| DB02901 | DRUGBANK_ID |
| 2856 | IUPHAR_LIGAND_ID |
| 238 | INN_ID |
| 08J2K08A3Y | UNII |
| 10635 | PUBCHEM_CID |
| 003255 | NDDF |
| 005232 | NDDF |
| 103042004 | SNOMEDCT_US |
| 56032002 | SNOMEDCT_US |
| D013196 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
None